Insight Molecular Diagnostics Inc.

For the period ended Sep 30, 2025. Filed Nov 10, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 10, 2025

IMDX$2.47-1.2%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share data)

	Three Months EndedSeptember 30,		Nine Months EndedSeptember 30,
	2025	2024	2025	2024
Net revenue	$260	$115	$2,916	$395
Cost of revenues	121	43	1,107	184
Cost of revenues – amortization of acquired intangibles	—	22	7	66
Gross profit	139	50	1,802	145
Operating expenses:
Research and development	3,878	2,817	10,071	7,582
Sales and marketing	1,386	1,043	4,052	2,742
General and administrative	2,545	2,565	8,307	7,645
Change in fair value of contingent consideration	3,378	7,140	7,061	9,421
Impairment loss on held for sale assets	—	—	—	169
Total operating expenses	11,187	13,565	29,491	27,559
Loss from operations	(11,048)	(13,515)	(27,689)	(27,414)
Other (expenses) income:
Interest expense	(29)	(31)	(83)	(54)
Other income, net	223	53	505	316
Total other income, net	194	22	422	262
Loss before income taxes	(10,854)	(13,493)	(27,267)	(27,152)
Income taxes	—	—	—	—
Net loss	$(10,854)	$(13,493)	$(27,267)	$(27,152)
Net loss per share (Note 2):
Net loss attributable to common stockholders - basic and diluted	$(10,854)	$(13,493)	$(27,267)	$(27,415)
Net loss attributable to common stockholders per share - basic and diluted	$(0.34)	$(0.98)	$(0.91)	$(2.36)
Weighted average shares outstanding - basic and diluted	32,033	13,714	29,940	11,624

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.